Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club! We’ll dive into two pivotal ILD studies: 📄 FIBRONEER (Nerandomilast in PPF) – NEJM 2025 📄 RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet Panelists: Dr. Toby Maher, Dr. Shervin Assassi Moderator: https://t.co/BebFhDJ1mM

Equal Safety of JAK Inhibitors and TNF Inhibitors JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for https://t.co/DTux5QdETS

When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/Kxbarq9tiD

STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months. https://t.co/wsnc9uZi1P https://t.co/MwZJAQs7Rt

🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis & monitoring 🧑⚕️ What rheums should know next ⬇️ Download & learn more: https://t.co/XNmbcfqKKF Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/Yhlw3nGsDh

Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/2r9oS1Eb9k https://t.co/GqKq5E0bmp

Call to Update the Classification Criteria in Idiopathic Inflammatory Myopathies (IMM), Why? - EULAR/ACR myositis criteria dont cover specific myositis subtypes - Polymyositis is rare - antisynthetase & necrotizing myopathy & Jo1 Dz not well represented - Need to include MSA, https://t.co/P9CEXmEOxl

SMART study - Single vs. Split Dose Methotrexate in RA Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients. https://t.co/K0C63GgHvn https://t.co/FTJ11fpKnB

Optimal glucocorticoid therapy in lupus nephritis 🔓https://t.co/e6SjmOrRpw ➡️This review provides an in-depth analysis of glucocorticoid therapy for lupus nephritis, a severe manifestation of systemic lupus erythematosus that affects up to 51.7% of patients https://t.co/JftCQiFif1

🎓 Learning just got smarter. Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates. 💡 Educational 🎯 Evidence-based 🧠 Addictive (in a good way) Try it now and level up your clinical knowledge: https://t.co/mVZhEpn3lo https://t.co/4cMTZXxsUk

Study of urinary soluble CD163 levels in 214 SLE pts (129 w/ LN), found urinary CD163 highly correlates w/ UPCR, active vs inactive states, predicts Renal Bx histologic activity (AUC 0.962) & renal dz flares & allows prediction of complete, partial and non-responders https://t.co/HNKAuFDgPG